Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Adjuvant Placebo Plus MK-3475A in Participants With Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer Following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)
Conditions
Interventions
Calderasib
MK-3475A
+1 more
Locations
14
Taiwan
National Cheng Kung University Hospital ( Site 3706)
Tainan, Taiwan
COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 1904)
Cherkasy, Cherkasy Oblast, Ukraine
Regional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center" ( Site 1909)
Chernivtsi, Chernivetska Oblast, Ukraine
Medical Center "Mriya Med-Service" ( Site 1911)
Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine
Communal Non-Commercial Enterprise Prykarpatski Clinical Oncological Center of Ivano-Frankivsk Regio ( Site 1900)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Private Enterprise Private Manufacturing Company Acinus-Medical and Diagnostic Centre ( Site 1916)
Kropyvnytskyi, Kirovohrad Oblast, Ukraine
Start Date
March 18, 2026
Primary Completion Date
October 26, 2039
Completion Date
October 26, 2039
Last Updated
April 20, 2026
NCT06427941
NCT07164313
NCT07361497
NCT07510724
NCT07487883
NCT06745882
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions